According to our findings, Penke et al. have shown that the increased NAD salvage pathway is involved in hepatic steatosis and supplementation with NAD precursors may aid to attenuate disease progression by promoting the NAD+-dependent Sirt1 activation thus highlighting the importance to maintain a sufficient hepatic NAD availability (23). This evidence concerns the gene SIRT1 and fatty liver disease.